Access to Medicine

Social Impact in Life Sciences: broadening Access to Medicine for patients

The pharmaceutical industry is transitioning toward a more sustainable and inclusive model, where health equity and social impact are becoming a growing component of value creation. Significant industry progress on ESG has been made already and is accelerating, with pharmaceutical companies focusing efforts on expanding access to their products and solutions: a pharma-specific topic that requires to rethink the existing access paradigm.

A momentum for the life sciences industry to act

In the health ecosystem, life sciences companies are recognized by all stakeholders to play a critical role in addressing health inequities, through their direct and indirect impacts on individual and community health.

We support life sciences companies as they embark on their journey towards a more inclusive model

Why Deloitte?

Interested in learning more?


Our experts

Stéphane Bazoche

Stéphane Bazoche

Partner, Head of the Life Sciences and Healthcare practice

Stéphane leads the Healthcare and Life Sciences practice in France. He has developed expertise in value optimization of life sciences products, driving the strategic and design choices for superior va... En savoir plus

Jessica Weddle

Jessica Weddle

Managing Partner, Monitor Deloitte

Jessica is Managing Partner in Monitor Deloitte’s Life Science Healthcare practice specialized in market access, pricing, and digital health. She regularly advises pharma companies on choices related ... En savoir plus